• Home
  • About Us
    • Mission and vision
    • Quality politics
    • Pharmacovigilance
  • Products
  • Blog
  • Contact Us
  • Español
Write to us

Leave us a message

We are ready to answer you as soon as possible!

    I consent to the processing of personal data and agree to the user agreement and privacy policy.

    Menu
    Home Traumatology ArthroVisc 40
    C+E Max
    C+E Max S/350.00 Original price was: S/350.00.S/300.00Current price is: S/300.00.
    Back to products
    Cellular Matrix BCT-HA
    Cellular Matrix BCT-HA
    Click to enlarge

    ArthroVisc 40

    ArthroVisc®40 is a non-cross-linked hyaluronic acid (2 %) obtained from bacterial fermentation.

    This product is sterile and non-pyrogenic.

    It is packaged in 2 ml syringes of hyaluronic acid ( 20 mg/ml, 1500 KDa).

    ArthroVisc®40 is available in three syringes of 2 ml. It is for single use and designed to be used with sterile needles (25G or 27G), not supplied in the kit.

    Composition :
    2 mL of solution contains 40mg of hyaluronic acid in phosphate buffer (Sodium chloride, Dipotassium hydrogenphosphate, Potassium dihydrogenphosphate, Potassium chloride) and water for injection.

    Category: Traumatology
    Share:
    • Description
    Description

    Intended use of the device

    Hyaluronic acid gel for intra-articular injections in the knee for the symptomatic treatment of joint pain and improvement of mobility.

    Contraindications

    Do not administer to patients with proven hypersensitivity to one of the components, or who suffer from a serious illness such as joint infection or acute/local infection at the procedure site. Administration is not recommended to patients suffering from inflammatory joint diseases such as rheumatoid arthritis or Bechterew’s disease.
    The administration of hyaluronic acid to children, pregnant or lactating women is not recommended.

    Precautions

    Injections into the joint cavity should be performed with the same precautions as any other intra-articular injection and, if necessary, using image monitoring. The patient must respect a delay of 1 hour without physical activity after the injection, and avoid strenuous or weight-bearing activities for 48 hours following the intra-articular injection.

    The patient should be informed about the general risks associated with the treatment and possible adverse effects. Injections must be performed by the doctor and under his/her responsibility. The doctor must be familiar with the equipment and the procedure before using the kit. Strictly aseptic injection technique must be followed. Use proper safety precautions to protect yourself from needles. Do not recap the needle after use and dispose of it directly in the biohazard container. Discard each syringe and remaining HA gel after use, using the disposal method for potentially contaminated products. Do not inject intravenously or for any application other than as described in the intended use. Do not use if packaging or syringes are open or damaged. Do not use after the expiration date. This product is for single use only: do not reuse.

    If the plunger becomes blocked during injection, do not force it; the injection should be stopped. The doctor must evaluate the need to adapt the treatment protocol according to the volume of hyaluronic acid gel that was injected.

    Possible side effects

    The injection may cause damage to blood vessels and bruising. Local secondary inflammatory reactions may occur at the injection site. This can cause phenomena such as temporary pain, a sensation of heat, redness and swelling in the treated joint. There have also been occasional reports of hypersensitivity, including, rarely, anaphylaxis. The application of ice packs in the minutes following the injection or local analgesic treatment the day after the injection can reduce these inconveniences.

     

    Related products

    Cellular Matrix A-CP-HA

    Traumatology
    Cellular Matrix® tubes allow the preparation of autologous platelet-rich plasma (RegenPRP®) combined with non-cross-linked hyaluronic acid (HA) in a closed-loop system. CM-PRP-HA has an excellent safety profile in clinical practice. Cellular Matrix® technology combines the complementary clinical effects of RegenPRP® and hyaluronic acid (HA), providing better, longer-lasting results in patients with osteoarthritis. Hyaluronic acid
    • Hyaluronic acid is an important component of synovial fluid that contributes to joint homeostasis.
    • 25 years of clinical experience shows pain relief and functional improvement lasting 6 to 12 months in patients with OA.
    • It plays an important role in viscosupplementation and pain relief in OA.
    • The network of HA chains generates an ideal matrix for cells when combined with PRP.
    • Hyaluronic acid enhances the activity of several molecules contained in platelet-rich plasma to provide additional benefits to OA patients.
    Read more
    Quick view

      Get answers to all your questions you may have

      We will resolve any questions you may have about our products.
      Write to us

      Leave us a message

      We are ready to answer you as soon as possible!

        I consent to the processing of personal data and agree to the user agreement and privacy policy.

        Vento y Montero is a leading and different Latin American pharmaceutical company, focused on the marketing and sale of cutting-edge specialized pharmaceutical products.

        Developed with love by GenioLibre

        • Menu
        • Categories
        • Dermoestética
        • Traumatologia
        • Dermatología
        • Nutriceuticos
        • Home
        • About Us
          • Mission and vision
          • Quality politics
          • Pharmacovigilance
        • Products
        • Blog
        • Contact Us
        • Español
        • Login / Register
        Shop
        0 items Cart
        My account